Matches in SemOpenAlex for { <https://semopenalex.org/work/W4281756812> ?p ?o ?g. }
Showing items 1 to 97 of
97
with 100 items per page.
- W4281756812 endingPage "e16260" @default.
- W4281756812 startingPage "e16260" @default.
- W4281756812 abstract "e16260 Background: Therapeutic inhibition of constitutive signaling mediated by mutated KRAS in PDAC remains a challenge except for modest success reported with KRAS G12C inhibition. A combinatorial strategy utilizing simultaneous MEK and autophagy inhibition holds therapeutic promise based on mechanism of action and preclinical data. We described characteristics and outcomes of patients (pts) treated with MEK-inh and HCQ at our institution. Methods: Ten KRAS-mutated advanced PDAC pts were treated with trametinib-HCQ (n = 9) or cobimetinib-HCQ (n = 1) off label due to lack of standard treatment options or toxicity concerns with cytotoxic systemic therapy. Trametinib dose was 2 mg once daily orally, Cobimetinib dose was 20 mg BID orally for 3/4 weeks cycles. HCQ was started at 200 mg BID and up-titrated weekly to 600 mg BID. Description of baseline and treatment (tx) characteristics, safety and efficacy is provided. Results: Median age at diagnosis was 61.3 years, and 7 pts were female. The number of prior lines of tx were 0/1/2/3/4 in 3/2/1/2/2 pts, respectively. KRAS mutations were: G12R/G12D/G12V/Q61H in 6/2/1/1 pts. Median overall survival was 6.6 months (m) in all pts, and 6.6/1.7 m in KRAS G12R/other KRAS (p = 0.31). Median progression-free survival was 5.7/6.2/1.5 m in all/ KRAS G12R/other KRAS (p = 0.16). Among 8 pts with evaluable response, 1 (12%) had partial response ( KRAS G12R) and 4 (50%) stable disease (3/4 KRAS G12R) as best response with disease control rate of 63%/80%/33% in total/ KRAS G12R/other KRAS (p = 0.29). Toxicity data are summarized in table 1. Conclusions: MEK-inh-HCQ demonstrated modest efficacy and manageable toxicities among KRAS G12R PDAC pts. Unlike G12D and G12V mutations in the KRAS gene, G12R is defective of conductive interactions for both PI3Ka and NF1. This ultimately results in a weakened signal being shunted through MAPK cascade and provides a unique opportunity where MEK inh can ablate signaling without the alternate pathways and WT-RAS isoforms compensating. Furthermore, as activation of PI3Ka is known to suppress autophagy, its lack of activation by KRAS G12R further sensitizes cells to HCQ. The combination therapy MEK-inh-HCQ is therefore mechanistically-rationale and warrants the further investigation of KRAS G12R as an actionable biomarker.[Table: see text]" @default.
- W4281756812 created "2022-06-13" @default.
- W4281756812 creator A5006174923 @default.
- W4281756812 creator A5013768762 @default.
- W4281756812 creator A5025094341 @default.
- W4281756812 creator A5026296352 @default.
- W4281756812 creator A5030283354 @default.
- W4281756812 creator A5036509408 @default.
- W4281756812 creator A5039041724 @default.
- W4281756812 creator A5041591287 @default.
- W4281756812 creator A5044766516 @default.
- W4281756812 creator A5053481267 @default.
- W4281756812 creator A5058977584 @default.
- W4281756812 creator A5059144599 @default.
- W4281756812 creator A5066121818 @default.
- W4281756812 creator A5069696721 @default.
- W4281756812 creator A5075239977 @default.
- W4281756812 creator A5076270097 @default.
- W4281756812 creator A5077050813 @default.
- W4281756812 creator A5078997248 @default.
- W4281756812 creator A5081736870 @default.
- W4281756812 creator A5083509294 @default.
- W4281756812 date "2022-06-01" @default.
- W4281756812 modified "2023-10-17" @default.
- W4281756812 title "MEK-inhibitor (inh) and hydroxychloroquine (HCQ) in <i>KRAS</i>-mutated advanced pancreatic ductal adenocarcinoma (PDAC)." @default.
- W4281756812 doi "https://doi.org/10.1200/jco.2022.40.16_suppl.e16260" @default.
- W4281756812 hasPublicationYear "2022" @default.
- W4281756812 type Work @default.
- W4281756812 citedByCount "2" @default.
- W4281756812 countsByYear W42817568122023 @default.
- W4281756812 crossrefType "journal-article" @default.
- W4281756812 hasAuthorship W4281756812A5006174923 @default.
- W4281756812 hasAuthorship W4281756812A5013768762 @default.
- W4281756812 hasAuthorship W4281756812A5025094341 @default.
- W4281756812 hasAuthorship W4281756812A5026296352 @default.
- W4281756812 hasAuthorship W4281756812A5030283354 @default.
- W4281756812 hasAuthorship W4281756812A5036509408 @default.
- W4281756812 hasAuthorship W4281756812A5039041724 @default.
- W4281756812 hasAuthorship W4281756812A5041591287 @default.
- W4281756812 hasAuthorship W4281756812A5044766516 @default.
- W4281756812 hasAuthorship W4281756812A5053481267 @default.
- W4281756812 hasAuthorship W4281756812A5058977584 @default.
- W4281756812 hasAuthorship W4281756812A5059144599 @default.
- W4281756812 hasAuthorship W4281756812A5066121818 @default.
- W4281756812 hasAuthorship W4281756812A5069696721 @default.
- W4281756812 hasAuthorship W4281756812A5075239977 @default.
- W4281756812 hasAuthorship W4281756812A5076270097 @default.
- W4281756812 hasAuthorship W4281756812A5077050813 @default.
- W4281756812 hasAuthorship W4281756812A5078997248 @default.
- W4281756812 hasAuthorship W4281756812A5081736870 @default.
- W4281756812 hasAuthorship W4281756812A5083509294 @default.
- W4281756812 hasConcept C121608353 @default.
- W4281756812 hasConcept C126322002 @default.
- W4281756812 hasConcept C143998085 @default.
- W4281756812 hasConcept C184235292 @default.
- W4281756812 hasConcept C2778472372 @default.
- W4281756812 hasConcept C2781187634 @default.
- W4281756812 hasConcept C2781249067 @default.
- W4281756812 hasConcept C526805850 @default.
- W4281756812 hasConcept C57074206 @default.
- W4281756812 hasConcept C71924100 @default.
- W4281756812 hasConcept C86803240 @default.
- W4281756812 hasConcept C95444343 @default.
- W4281756812 hasConcept C98274493 @default.
- W4281756812 hasConceptScore W4281756812C121608353 @default.
- W4281756812 hasConceptScore W4281756812C126322002 @default.
- W4281756812 hasConceptScore W4281756812C143998085 @default.
- W4281756812 hasConceptScore W4281756812C184235292 @default.
- W4281756812 hasConceptScore W4281756812C2778472372 @default.
- W4281756812 hasConceptScore W4281756812C2781187634 @default.
- W4281756812 hasConceptScore W4281756812C2781249067 @default.
- W4281756812 hasConceptScore W4281756812C526805850 @default.
- W4281756812 hasConceptScore W4281756812C57074206 @default.
- W4281756812 hasConceptScore W4281756812C71924100 @default.
- W4281756812 hasConceptScore W4281756812C86803240 @default.
- W4281756812 hasConceptScore W4281756812C95444343 @default.
- W4281756812 hasConceptScore W4281756812C98274493 @default.
- W4281756812 hasIssue "16_suppl" @default.
- W4281756812 hasLocation W42817568121 @default.
- W4281756812 hasOpenAccess W4281756812 @default.
- W4281756812 hasPrimaryLocation W42817568121 @default.
- W4281756812 hasRelatedWork W2212221772 @default.
- W4281756812 hasRelatedWork W2312667856 @default.
- W4281756812 hasRelatedWork W2474854223 @default.
- W4281756812 hasRelatedWork W2741304831 @default.
- W4281756812 hasRelatedWork W2756705158 @default.
- W4281756812 hasRelatedWork W2992555522 @default.
- W4281756812 hasRelatedWork W4225272646 @default.
- W4281756812 hasRelatedWork W4225463380 @default.
- W4281756812 hasRelatedWork W4309889913 @default.
- W4281756812 hasRelatedWork W4311937555 @default.
- W4281756812 hasVolume "40" @default.
- W4281756812 isParatext "false" @default.
- W4281756812 isRetracted "false" @default.
- W4281756812 workType "article" @default.